{"id":449,"date":"2026-08-27T10:31:11","date_gmt":"2026-08-27T10:31:11","guid":{"rendered":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/"},"modified":"2026-08-28T07:42:46","modified_gmt":"2026-08-28T07:42:46","slug":"retatrutide-triple-agonist-phase-2-evidence","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/cn\/retatrutide-triple-agonist-phase-2-evidence\/","title":{"rendered":"Retatrutide \u4e09\u91cd\u6fc0\u52a8\uff1a2 \u9636\u6bb5\u8bd5\u9a8c\u53d1\u73b0\u4f46\u672a\u8bc1\u660e\u7684\u5185\u5bb9"},"content":{"rendered":"<p class=\"pim-standfirst wp-block-paragraph\">Retatrutide \u65e8\u5728\u6fc0\u6d3b\u4e00\u4e2a\u5206\u5b50\u4e2d\u7684 GIP\u3001GLP-1 \u548c\u80f0\u9ad8\u8840\u7cd6\u7d20\u53d7\u4f53\u3002\u5176 2023 \u9636\u6bb5 2 \u80a5\u80d6\u8bd5\u9a8c\u5f15\u8d77\u4e86\u6781\u5927\u7684\u5174\u8da3\uff0c\u4f46\u6b63\u786e\u7684\u89e3\u91ca\u53d6\u51b3\u4e8e\u8bd5\u9a8c\u9636\u6bb5\u3001\u4eba\u7fa4\u3001\u7ec8\u70b9\u3001\u4e0d\u826f\u4e8b\u4ef6\u53d1\u73b0\u4ee5\u53ca\u5c1a\u4e0d\u6e05\u695a\u7684\u5185\u5bb9\u3002<\/p><div class=\"wp-block-group pim-key-takeaways\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 class=\"wp-block-heading\">\u8981\u70b9<\/h2><ul class=\"wp-block-list\"><li>Retatrutide \u662f\u4e00\u79cd\u5355\u4e00\u7814\u7a76\u5206\u5b50\uff0c\u5bf9\u4e09\u79cd\u6fc0\u7d20\u53d7\u4f53\u5177\u6709\u6d3b\u6027\u3002<\/li><li>\u7ecf\u5e38\u5f15\u7528\u7684\u7ed3\u679c\u6765\u81ea 338 \u53c2\u4e0e\u8005\u9636\u6bb5 2 \u8bd5\u9a8c\uff0c\u800c\u4e0d\u662f\u6279\u51c6\u51b3\u5b9a\u3002<\/li><li>3 \u9636\u6bb5\u7814\u7a76\u7684\u5b8c\u6210\u672c\u8eab\u5e76\u4e0d\u610f\u5473\u7740\u7ed3\u679c\u5df2\u53d1\u5e03\u6216\u4ea7\u54c1\u5df2\u83b7\u5f97\u6279\u51c6\u3002<\/li><\/ul><\/div><\/div><figure class=\"wp-block-image size-full pim-article-figure\"><img loading=\"lazy\" decoding=\"async\" width=\"1672\" height=\"941\" src=\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research.png\" alt=\"\u7814\u7a76\u4eba\u5458\u5728\u5206\u5b50\u751f\u7269\u5b66\u5b9e\u9a8c\u5ba4\u5ba1\u67e5\u4e09\u79cd\u80bd\u53d7\u4f53\u4fe1\u53f7\u901a\u8def\" class=\"wp-image-442\" srcset=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research.png 1672w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research-300x169.png 300w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research-1024x576.png 1024w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research-768x432.png 768w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research-1536x864.png 1536w\" sizes=\"auto, (max-width: 1672px) 100vw, 1672px\" \/><figcaption class=\"wp-element-caption\">\u7814\u7a76\u5b9e\u9a8c\u5ba4\u4e2d\u4e09\u79cd\u53d7\u4f53\u4fe1\u53f7\u4f20\u5bfc\u9014\u5f84\u7684\u539f\u59cb\u793e\u8bba\u63d2\u56fe\uff1b\u4e0d\u662f\u4e34\u5e8a\u7ed9\u836f\u7684\u63cf\u8ff0\u3002<\/figcaption><\/figure><h2 class=\"wp-block-heading\">\u4e09\u53d7\u4f53\u6982\u5ff5<\/h2><p class=\"wp-block-paragraph\">Retatrutide\uff0c\u5728\u5f00\u53d1\u8bb0\u5f55\u4e2d\u4e5f\u88ab\u786e\u5b9a\u4e3a LY3437943\uff0c\u662f GIP\u3001GLP-1 \u548c\u80f0\u9ad8\u8840\u7cd6\u7d20\u53d7\u4f53\u7684\u6fc0\u52a8\u5242\u3002\u5c06\u5176\u79f0\u4e3a\u4e09\u91cd\u6fc0\u52a8\u5242\u63cf\u8ff0\u4e86\u53d7\u4f53\u836f\u7406\u5b66\uff1b\u5b83\u672c\u8eab\u5e76\u4e0d\u80fd\u9884\u6d4b\u7279\u5b9a\u4eba\u7fa4\u4e2d\u7ed3\u679c\u7684\u7a0b\u5ea6\u3001\u6301\u4e45\u6027\u6216\u5b89\u5168\u6027\u3002<\/p><p class=\"wp-block-paragraph\">\u4e09\u79cd\u53d7\u4f53\u7684\u6d3b\u6027\u5e73\u8861\u3001\u5206\u5b50\u7684\u66b4\u9732\u66f2\u7ebf\u548c\u7814\u7a76\u7684\u914d\u65b9\u90fd\u6709\u52a9\u4e8e\u89c2\u5bdf\u5230\u7684\u6548\u679c\u3002<\/p><h2 class=\"wp-block-heading\">2 \u9636\u6bb5\u7814\u7a76\u6d4b\u91cf\u4e86\u4ec0\u4e48<\/h2><p class=\"wp-block-paragraph\">\u8fd9\u9879\u968f\u673a\u3001\u53cc\u76f2\u3001\u5b89\u6170\u5242\u5bf9\u7167\u8bd5\u9a8c\u62db\u52df\u4e86\u60a3\u6709\u80a5\u80d6\u75c7\u6216\u8d85\u91cd\u4e14\u60a3\u6709\u4f53\u91cd\u76f8\u5173\u75be\u75c5\u7684 338 \u6210\u5e74\u4eba\u3002\u4e3b\u8981\u7ec8\u70b9\u662f 24 \u5468\u65f6\u4f53\u91cd\u7684\u767e\u5206\u6bd4\u53d8\u5316\uff1b 48 \u5468\u53d8\u5316\u548c\u5206\u7c7b\u4f53\u91cd\u51cf\u8f7b\u9608\u503c\u662f\u6b21\u8981\u7ec8\u70b9\u3002\u80c3\u80a0\u9053\u4e8b\u4ef6\u662f\u6700\u5e38\u89c1\u7684\u4e0d\u826f\u4e8b\u4ef6\uff0c\u89c2\u5bdf\u5230\u5242\u91cf\u4f9d\u8d56\u6027\u5fc3\u7387\u589e\u52a0\uff0c\u7136\u540e\u5728\u7814\u7a76\u540e\u671f\u4e0b\u964d\u3002<\/p><p class=\"wp-block-paragraph\">\u8be5\u7814\u7a76\u5efa\u7acb\u4e86\u5242\u91cf\u53cd\u5e94\u4fe1\u53f7\u5e76\u652f\u6301 3 \u9636\u6bb5\u7684\u5f00\u53d1\u3002\u5b83\u6ca1\u6709\u5728\u66f4\u5e7f\u6cdb\u7684\u4eba\u7fa4\u4e2d\u5efa\u7acb\u957f\u671f\u7684\u5229\u76ca\u98ce\u9669\uff0c\u76f8\u5bf9\u4e8e\u6bcf\u79cd\u66ff\u4ee3\u65b9\u6848\u7684\u76f4\u63a5\u4f18\u52bf\uff0c\u6216\u8005\u8bd5\u9a8c\u6750\u6599\u548c\u76ee\u5f55\u4ea7\u54c1\u4e4b\u95f4\u7684\u7b49\u6548\u6027\u3002<\/p><div class=\"wp-block-group pim-evidence-table\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><div class=\"pim-evidence-row\"><strong>\u8bbe\u8ba1<\/strong><span>\u968f\u673a\u3001\u53cc\u76f2\u3001\u5b89\u6170\u5242\u5bf9\u7167 2 \u671f\u8bd5\u9a8c<\/span><\/div><div class=\"pim-evidence-row\"><strong>\u53c2\u52a0\u8005<\/strong><span>338 \u6210\u4eba<\/span><\/div><div class=\"pim-evidence-row\"><strong>\u671f\u95f4<\/strong><span>48\u5468<\/span><\/div><div class=\"pim-evidence-row\"><strong>\u5173\u952e\u8fb9\u754c<\/strong><span>\u7814\u7a76\u8bc1\u636e\uff0c\u800c\u975e FDA \u6279\u51c6<\/span><\/div><\/div><\/div><h2 class=\"wp-block-heading\">2026 \u6539\u53d8\u4e86\u4ec0\u4e48<\/h2><p class=\"wp-block-paragraph\">ClinicalTrials.gov \u5c06 TRIUMPH-1 \u5217\u4e3a\u5df2\u5b8c\u6210\u7684 3 \u9636\u6bb5\u7814\u7a76\uff0c\u7814\u7a76\u4e8e 4 \u6708\u5b8c\u6210 2026\uff0c\u4f46\u672c\u6587\u5ba1\u67e5\u7684\u8bb0\u5f55\u4e2d\u6ca1\u6709\u53d1\u5e03\u4efb\u4f55\u7ed3\u679c\u3002 \u201c\u5df2\u5b8c\u6210\u201d\u63cf\u8ff0\u4e86\u5b66\u4e60\u72b6\u6001\uff1b\u5b83\u4e0d\u80fd\u66ff\u4ee3\u7ed3\u679c\u3001\u540c\u884c\u8bc4\u5ba1\u6216\u76d1\u7ba1\u8bc4\u4f30\u3002<\/p><p class=\"wp-block-paragraph\">FDA\u76ee\u524d\u7684\u516c\u5f00\u4fe1\u606f\u8868\u660e\uff0c\u745e\u4ed6\u9c81\u80bd\u4e0d\u662fFDA\u6279\u51c6\u7684\u836f\u7269\u7684\u6210\u5206\u3002\u56e0\u6b64\uff0c\u51c6\u786e\u7684 2026 \u6587\u7ae0\u5e94\u5c06\u5176\u63cf\u8ff0\u4e3a\u7814\u7a76\u6027\u7684\uff0c\u9664\u975e\u6743\u5a01\u6279\u51c6\u8bb0\u5f55\u53e6\u6709\u8bf4\u660e\u3002<\/p><h2 class=\"wp-block-heading\">2026 \u8d5e\u52a9\u5546\u62a5\u544a\u7684\u9636\u6bb5 3 \u9876\u7ebf<\/h2><p class=\"wp-block-paragraph\">\u793c\u6765\u516c\u53f8\u4e8e 5 \u6708\u62a5\u544a\u4e86 TRIUMPH-1 \u7684\u4e3b\u8981\u7ed3\u679c 21\u30012026\uff1a\u5728 80 \u5468\uff0c\u7533\u529e\u8005\u62a5\u544a 12 \u6beb\u514b\u7ec4\u7684\u5e73\u5747\u4f53\u91cd\u53d8\u5316\u4e3a -28.3%\u3002 7 \u6708 23\u30012026\uff0c\u793c\u6765\u516c\u53f8\u62a5\u544a\u4e86 TRIUMPH-2 \u4e2d\u7684\u5e73\u5747\u53d8\u5316\u4e3a -20.8%\uff0cTRIUMPH-3 \u4e2d\u7684\u5e73\u5747\u53d8\u5316\u4e3a -22.6%\u3002\u8fd9\u4e9b\u662f\u4e3b\u8981\u7533\u529e\u65b9\u62ab\u9732\u7684\u4fe1\u606f\uff0c\u800c\u4e0d\u662f ClinicalTrials.gov \u7ed3\u679c\u6a21\u5757\u6216\u5b8c\u6574\u7684\u540c\u884c\u8bc4\u5ba1\u62a5\u544a\uff1b\u8be6\u7ec6\u7684\u65b9\u6cd5\u3001\u5206\u6790\u51b3\u7b56\u548c\u5b8c\u6574\u7684\u4e0d\u826f\u4e8b\u4ef6\u8868\u4ecd\u7136\u9700\u8981\u6700\u7ec8\u7684\u5b8c\u6574\u8bb0\u5f55\u3002 ClinicalTrials.gov \u5728\u672c\u6b21\u5ba1\u67e5\u4e2d\u7ee7\u7eed\u663e\u793a TRIUMPH-1\u201c\u672a\u53d1\u5e03\u7ed3\u679c\u201d\u3002<\/p>","protected":false},"excerpt":{"rendered":"<p>\u4ed4\u7ec6\u9605\u8bfb\u745e\u4ed6\u9c81\u80bd\u7684 GIP\u3001GLP-1 \u548c\u80f0\u9ad8\u8840\u7cd6\u7d20\u53d7\u4f53\u836f\u7406\u5b66\u4ee5\u53ca 48 \u5468\u671f 2 \u80a5\u80d6\u8bd5\u9a8c\uff0c\u5305\u62ec\u5c40\u9650\u6027\u548c\u5f53\u524d\u7814\u7a76\u72b6\u6001\u3002<\/p>","protected":false},"author":1,"featured_media":619,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"359","pim_article_type":"Clinical trial evidence review","pim_evidence_level":"Randomized phase 2 human trial; investigational status","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-28","pim_editorial_note":"Source-checked against the linked primary or authoritative records on 2026-08-27. This is an evidence summary, not independent peer review, medical advice or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"Triple-Hormone-Receptor Agonist Retatrutide for Obesity \u2014 phase 2 trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37366315\/\",\"note\":\"Primary randomized phase 2 record; PMID 37366315.\"},{\"title\":\"TRIUMPH-1 phase 3 study record\",\"url\":\"https:\/\/clinicaltrials.gov\/study\/NCT05929066\",\"note\":\"ClinicalTrials.gov record updated June 2026; results not posted in the reviewed record.\"},{\"title\":\"FDA information on unapproved GLP-1 products\",\"url\":\"https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss\",\"note\":\"Current regulatory-status boundary.\"},{\"title\":\"TRIUMPH-1 sponsor-reported topline results\",\"url\":\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss\",\"note\":\"Lilly primary-sponsor news release, May 21, 2026; not a peer-reviewed full report.\"},{\"title\":\"TRIUMPH-2 and TRIUMPH-3 sponsor-reported topline results\",\"url\":\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-successful-two-additional\",\"note\":\"Lilly primary-sponsor news release, July 23, 2026; detailed results remain pending.\"}]","footnotes":""},"categories":[18],"tags":[],"class_list":["post-449","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-reviews"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove - NHD<\/title>\n<meta name=\"description\" content=\"A close reading of retatrutide\u2019s GIP, GLP-1 and glucagon receptor pharmacology and the 48-week phase 2 obesity trial, including limitations and current investigational status.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/cn\/retatrutide-triple-agonist-phase-2-evidence\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove\" \/>\n<meta property=\"og:description\" content=\"A close reading of retatrutide\u2019s GIP, GLP-1 and glucagon receptor pharmacology and the 48-week phase 2 obesity trial, including limitations and current investigational status.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/cn\/retatrutide-triple-agonist-phase-2-evidence\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T10:31:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:42:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:42:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/\"},\"wordCount\":444,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp\",\"articleSection\":[\"Evidence Reviews\"],\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/\",\"name\":\"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:42:46+00:00\",\"description\":\"A close reading of retatrutide\u2019s GIP, GLP-1 and glucagon receptor pharmacology and the 48-week phase 2 obesity trial, including limitations and current investigational status.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/cn\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Retatrutide \u4e09\u91cd\u6fc0\u52a8\uff1a2 \u9636\u6bb5\u8bd5\u9a8c\u53d1\u73b0\u4f46\u672a\u8bc1\u660e\u7684\u5185\u5bb9 - NHD","description":"\u4ed4\u7ec6\u9605\u8bfb\u745e\u4ed6\u9c81\u80bd\u7684 GIP\u3001GLP-1 \u548c\u80f0\u9ad8\u8840\u7cd6\u7d20\u53d7\u4f53\u836f\u7406\u5b66\u4ee5\u53ca 48 \u5468\u671f 2 \u80a5\u80d6\u8bd5\u9a8c\uff0c\u5305\u62ec\u5c40\u9650\u6027\u548c\u5f53\u524d\u7814\u7a76\u72b6\u6001\u3002","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/cn\/retatrutide-triple-agonist-phase-2-evidence\/","og_locale":"zh_CN","og_type":"article","og_title":"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove","og_description":"A close reading of retatrutide\u2019s GIP, GLP-1 and glucagon receptor pharmacology and the 48-week phase 2 obesity trial, including limitations and current investigational status.","og_url":"https:\/\/nhdbio.com\/cn\/retatrutide-triple-agonist-phase-2-evidence\/","og_site_name":"NHD","article_published_time":"2026-08-27T10:31:11+00:00","article_modified_time":"2026-08-28T07:42:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"\u4f5c\u8005":"NHD Technical Team","\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"2 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:42:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/"},"wordCount":444,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp","articleSection":["Evidence Reviews"],"inLanguage":"zh-Hans","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/","url":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/","name":"Retatrutide \u4e09\u91cd\u6fc0\u52a8\uff1a2 \u9636\u6bb5\u8bd5\u9a8c\u53d1\u73b0\u4f46\u672a\u8bc1\u660e\u7684\u5185\u5bb9 - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:42:46+00:00","description":"\u4ed4\u7ec6\u9605\u8bfb\u745e\u4ed6\u9c81\u80bd\u7684 GIP\u3001GLP-1 \u548c\u80f0\u9ad8\u8840\u7cd6\u7d20\u53d7\u4f53\u836f\u7406\u5b66\u4ee5\u53ca 48 \u5468\u671f 2 \u80a5\u80d6\u8bd5\u9a8c\uff0c\u5305\u62ec\u5c40\u9650\u6027\u548c\u5f53\u524d\u7814\u7a76\u72b6\u6001\u3002","breadcrumb":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"\u591a\u80bd\u539f\u6599\u4e0e\u591a\u80bd\u5b9a\u5236\u5408\u6210","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"NHD\u6280\u672f\u56e2\u961f","image":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"NHD \u6280\u672f\u56e2\u961f\u7ef4\u62a4\u7814\u7a76\u7528\u9014\u76ee\u5f55\u6587\u6863\u548c\u8bc1\u636e\u6458\u8981\u3002\u7ecf\u8bc4\u5ba1\u7684\u6587\u7ae0\u94fe\u63a5\u5230\u540c\u884c\u8bc4\u5ba1\u7684\u8bba\u6587\u3001\u8bd5\u9a8c\u6ce8\u518c\u548c\u76d1\u7ba1\u8bb0\u5f55\uff0c\u4fdd\u7559\u65e0\u6548\u7ed3\u679c\u548c\u7814\u7a76\u5c40\u9650\u6027\uff0c\u5e76\u5c06\u5df2\u53d1\u8868\u7684\u5e72\u9884\u63aa\u65bd\u4e0e\u76ee\u5f55\u6750\u6599\u533a\u5206\u5f00\u6765\u3002\u7ed3\u6784\u53ef\u91c7\u7528AI\u8f85\u52a9\u7ed8\u56fe\uff1b\u6765\u6e90\u94fe\u63a5\u548c\u8bc1\u636e\u8fb9\u754c\u4ecd\u7136\u53ef\u89c1\u3002\u8fd9\u9879\u5de5\u4f5c\u4e0d\u662f\u72ec\u7acb\u7684\u540c\u884c\u8bc4\u5ba1\u6216\u533b\u7597\u5efa\u8bae\u3002","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/cn\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/cn\/wp-json\/wp\/v2\/posts\/449","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/cn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/cn\/wp-json\/wp\/v2\/comments?post=449"}],"version-history":[{"count":2,"href":"https:\/\/nhdbio.com\/cn\/wp-json\/wp\/v2\/posts\/449\/revisions"}],"predecessor-version":[{"id":528,"href":"https:\/\/nhdbio.com\/cn\/wp-json\/wp\/v2\/posts\/449\/revisions\/528"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/cn\/wp-json\/wp\/v2\/media\/619"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/cn\/wp-json\/wp\/v2\/media?parent=449"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/cn\/wp-json\/wp\/v2\/categories?post=449"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/cn\/wp-json\/wp\/v2\/tags?post=449"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}